On May 25, 2022 Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, reported that Lisa Anson, Chief Executive Officer, and Peter Collum, Chief Financial Officer, will be presenting in-person at the Jefferies Global Healthcare Conference in New York on Wednesday 8 June 2022 at 9:30am ET / 14:30 GMT (Press release, Redx Pharma, MAY 25, 2022, View Source [SID1234615024]). Alongside the presentation, the Company will also be available for one-to-one meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed via the following link: View Source Following the event, a recording will be made available on the investor section of the Company’s website at: View Source

On May 25, 2022 RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, reported a $50 million private investment in public equity (PIPE) financing from the sale of pre-funded warrants to purchase up to 4 million shares of its common stock at a price per pre-funded warrant of $12.4999 to Redmile Group, based on the closing price per share of RAPT on May 24, 2022 (Press release, RAPT Therapeutics, MAY 25, 2022, https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-announces-private-placement-financing-50 [SID1234615023]). Gross proceeds from the PIPE financing total approximately $50 million, before deducting offering expenses. The closing of the PIPE financing is subject to customary closing conditions and is expected to close on May 27, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The shares of common stock underlying the pre-funded warrants have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. RAPT has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock underlying the pre-funded warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On May 25, 2022 Oxford Vacmedix UK Limited (OVM) reported the award of a Small Business Research Initiative contract from Innovate UK to fund research into the development of novel T-cell based potency assays (Press release, Oxford Vacmedix, MAY 25, 2022, View Source;utm_medium=rss&utm_campaign=innovate-uk-funding-for-development-of-novel-t-cell-potency-assays [SID1234615022]). These assays will support the development of vaccines for diseases of epidemic potential using the company’s proprietary recombinant overlapping peptide (ROP) technology and will pave the way for more cost-effective, rapid testing and improved control of manufacturing for vaccines. This is particularly important in the development of new vaccines for low- and middle-income countries and the findings may also be important in cancer research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

One of the key issues in vaccine development is the need for potency assays for Quality Control release and stability testing. Traditionally, in vivo testing is used to determine vaccine potency; however, these assays are time-consuming and costly and can show high variability. Cell-based potency assays are typically more reliable and have significantly reduced costs. This project will demonstrate a platform application, so that the assay format can be modified for use with different vaccine antigens including those with epidemic potential. The research will be carried out in collaboration with the Department of Oncology at the University of Oxford and with RSSL.

Spun out from the University of Oxford, OVM is commercialising the research on ROPs developed initially in the University. The principal application of the ROP platform technology is the development of novel therapeutic cancer vaccines with the potential for increased efficacy, simpler regulatory pathways and lower costs. OVM’s lead cancer vaccine, OVM-200 which targets survivin, is in a Phase 1 clinical trial in the UK for solid tumours.

This research is funded by the Department of Health and Social Care as part of the UK Vaccine Network (UKVN), a UK Aid programme to develop vaccines for diseases with epidemic potential in low- and middle-income countries.

Dr Shisong Jiang, CSO and Founder of OVM, said:

"We are very pleased to have received the support from Innovate UK and this funding from the UK Vaccine Network to enable work on this important project to be undertaken. The development of this novel potency assay technology could demonstrate real utility in the development of vaccines for diseases of epidemic potential and be a valuable addition for the progression of all vaccines that employ T cells in the immune response, such as our cancer vaccines."

Professor Xiao-Ning Xu, Chair in Human Immunology, Imperial College, London: added:

"This project is an excellent opportunity to widen the applications of the Oxford Vacmedix’s ROP technology and to build on the company’s expertise in immunology and infectious disease. We look forward to a successful outcome and to these novel assays being able to speed up the development of new vaccines as prophylactics or therapies for cancer and infectious disease".

On May 25, 2022 Genomic Testing Cooperative (GTC) reported it received CE-IVD marks for its Hematology Profile Plus, Solid Tumor Plus as well as its liquid biopsy profiles for both solid tumors and hematology that are designed to provide a wide range of clinically actionable insights about a patient’s tumor (Press release, Genomic Testing Cooperative, MAY 25, 2022, View Source [SID1234615021]). The CE mark will allow GTC and its partner, TherapySelect (Heidelberg, Germany), to make available GTC’s menu of DNA and targeted transcriptome profiling for patients in Europe. The Solid Tumor Profile Plus provides information on targetable mutations, fusion genes, tumor cell of origin, and the presence or absence of homologous recombination deficiency (HRD). The Hematology Profile Plus provides molecular data for selecting targeted therapy and also accurate diagnosis and classification of various myeloid and lymphoid neoplasms including gene fusions, chromosomal gains and losses, and molecular immunoprofiling. The Hematology Liquid Biopsy Profile is designed to reduce the need for bone marrow biopsy in certain circumstances. The Solid Tumor Liquid Biopsy Profile is designed for tumor-informed monitoring.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to expand our molecular profiling offerings to Europe and to make membership in the Cooperative available internationally. This will strengthen the network and accelerate innovation by building broader knowledge-based artificial intelligence algorithms," stated Dr. Maher Albitar, Founder, Chief Executive Officer and Chief Medical Officer, GTC.

Dr. Frank Kischkel, Managing Director and Scientific Director at TherapySelect stated, "We elected to partner with GTC because of the superior quality and comprehensive offering of the tests along with their commitment to innovation. GTC tests are designed with patients and best practices in oncology in mind. In addition, the co-op business model allows us to internalize the testing in our laboratories as our volumes grow in Europe. We are very excited to be GTC’s authorized representative in Europe and look forward to growing our partnership."

TherapySelect will be the authorized representative in the EU to offer CE certified in vitro diagnostic medical devices. Membership in the Co-Op allows other member labs to internalize GTC testing, which now includes the EU and countries recognizing the CE mark.

On May 25, 2022 AbbVie (NYSE: ABBV) reported that it will participate in the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1, 2022 (Press release, AbbVie, MAY 25, 2022, View Source [SID1234615020]). Richard A. Gonzalez, chairman and chief executive officer, will present at 10:00 a.m. Central Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.